SINGAPORE, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Bitdeer Technologies Group (Nasdaq: BTDR) (“Bitdeer”), a world-leading technology company for Bitcoin mining and AI infrastructure, today announced the pricing of US$325.0 million principal amount of 5.00% Convertible Senior Notes due 2032 (the “notes”) in a private placement (the “notes offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The aggr ...

NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced that Chemtrade Logistics Income Fund (TSX: CHE.UN; OTCQX: CGIFF), a diversified operator and producer of industrial chemicals and services, has qualified to trade on the OTCQX® Best Market. Chemtrade Logistics Income Fund upgraded to OTCQX from the Pink Limited™ Market. Chemtrade Logistics Income Fund begins trading today on OTC ...

Group 1 - Frontline plc will release its preliminary fourth quarter 2025 results on February 27, 2026 [1] - A webcast and conference call will be held at 3:00 p.m. CET (9:00 a.m. U.S. Eastern Time) [1] - The results presentation will be available for download from the Investor Relations section of the company's website [1] Group 2 - Participants can attend the conference call via webcast or by registering online for the conference call [2] - A Q&A session will follow the teleconference/webcast, with instructions for submitting questions provided at the beginning [2] - Presentation materials for the teleconference/webcast can be downloaded from the company's website [2]

Company Overview - Eton Pharmaceuticals, Inc is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases [3] - The company currently has eight commercial rare disease products: KHINDIVI™, INCRELEX, ALKINDI SPRINKLE, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone [3] - Eton has four additional product candidates in late-stage development: Amglidia, ET-700, ET-800, and ZENEO hydrocortisone autoinjector [3] Upcoming Events - Members of Eton's executive leadership team will host one-on-one meetings at the Leerink Partners Global Healthcare Conference on March 11, 2026, in Miami, Florida [1] - Interested parties can schedule a meeting by contacting their Leerink Partners institutional sales representative [2]

Company Overview - Eton Pharmaceuticals, Inc is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases [3] - The company currently has eight commercial rare disease products, including KHINDIVI™, INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone [3] - Eton has four additional product candidates in late-stage development: Amglidia®, ET-700, ET-800, and ZENEO® hydrocortisone autoinjector [3] Upcoming Events - Members of Eton's executive leadership team will host one-on-one meetings at the Leerink Partners Global Healthcare Conference on March 11, 2026, in Miami, Florida [1] - Interested parties can schedule a meeting by contacting their Leerink Partners institutional sales representative [2]

Core Viewpoint - Costamare Bulkers Holdings Limited reported its financial results for Q4 2025, showing an adjusted net loss of $1.7 million and total voyage revenue of $218.5 million, reflecting its performance as an independent publicly traded company after its spin-off from Costamare Inc. [2][7][15] Financial Highlights and Operational Updates - The company had a total debt of $155.6 million and cash of $226.3 million, resulting in a negative net debt position of $70.7 million as of the end of Q4 2025 [4][16]. - Total liquidity as of December 31, 2025, was approximately $311.0 million, including cash and undrawn funds [5][54]. - The average number of vessels in the owned fleet during Q4 2025 was 31.1, with ownership days totaling 2,859 [32][33]. Profitability and Revenue - Total voyage revenue for the year ended December 31, 2025, was $597.2 million, with voyage revenue for Q4 2025 at $218.5 million [21][37]. - The company reported voyage expenses of $45.2 million and charter-in hire expenses of $133.4 million for Q4 2025 [39][40]. - The adjusted net loss for the year was $12.2 million, with an adjusted loss per share of $0.74 [21][27]. Fleet and Operations - Costamare Bulkers currently owns a fleet of 31 dry bulk vessels with a total capacity of approximately 2.8 million DWT [59]. - The company has agreed to acquire a 2018-built dry bulk vessel, Koushun, expected to conclude within Q1 - Q2 2026 [10][20]. - The fleet includes various types of vessels, with the majority on period charters, and the average age of the fleet is approximately 13 years [16][19]. Strategic Developments - The company concluded a Strategic Cooperation Agreement with Cargill, transferring a significant portion of its trading portfolio, which included chartered-in vessels and cargo transportation commitments [8][15]. - The operating platform is now focused on Kamsarmax-type vessels, with plans for future acquisitions and fleet renewal [8][20]. Cash Flow and Financial Position - Net cash provided by operating activities for Q4 2025 was $26.4 million, while net cash provided by investing activities was $8.6 million [49][50]. - The company used $3.9 million in financing activities, primarily for debt payments [52]. Market Conditions - The Capesize index has increased due to favorable supply and demand fundamentals, while the Panamax index has benefited from easing US-China tensions [20]. - The Supramax index remains healthy, supported by strong demand for coal and minor bulks [21].

Core Viewpoint - Costamare Bulkers Holdings Limited reported its financial results for Q4 2025, showing an adjusted net loss of $1.7 million and highlighting its operational transition following its spin-off from Costamare Inc. [1][2][15] Financial Highlights and Operational Updates - The company had a total debt of $155.6 million and cash of $226.3 million, resulting in a negative net debt position of $70.7 million as of the end of Q4 2025 [4][16]. - Total voyage revenue for the year ended December 31, 2025, was $597.2 million, with Q4 2025 contributing $218.5 million [20][38]. - The average number of vessels in the owned fleet during Q4 2025 was 31.1, with ownership days totaling 2,859 [32][37]. Operating Platform and Strategic Agreements - The company concluded a Strategic Cooperation Agreement with Cargill, transferring a significant portion of its trading portfolio, including chartered-in vessels and cargo transportation commitments [8][15]. - The operating platform is currently focused on Kamsarmax-type vessels, with a fleet that includes 20 third-party owned dry bulk vessels [8][19]. Fleet Renewal and Vessel Transactions - Costamare Bulkers agreed to sell the 2011-built Capesize vessel, Miracle, and the 2008-built Supramax vessel, Clara, generating total capital gains of $7.7 million [17][18]. - The company has also agreed to acquire the 2018-built dry bulk vessel, Koushun, expected to conclude within Q1 - Q2 2026 [10][17]. Market Conditions - The Capesize index has increased due to favorable supply and demand fundamentals, supported by strong exports and improved sentiment [20]. - The Panamax index has benefited from easing US-China tensions and a strong Capesize market, while the Supramax index remains healthy due to strong demand for coal and minor bulks [20].

Group 1 - Essent Group Ltd. announced the appointment of Martin Connor to its Board of Directors, highlighting his expertise in real estate and finance as valuable for the company's growth and shareholder value [1] - Martin Connor has extensive experience in the real estate sector, having served as Chief Financial Officer of Toll Brothers from 2010 to 2025 and currently as a senior advisor [1] - Connor's previous roles include leadership positions at Marcon Advisors LLC and O'Neill Properties, as well as over 20 years at Ernst & Young LLP, where he was a partner responsible for the real estate practice [1] Group 2 - Essent Group Ltd. is a Bermuda-based holding company that provides private mortgage insurance, reinsurance, and title insurance services to the housing finance industry [2] - The company operates through its subsidiaries and aims to serve the needs of the housing finance sector [2]

Core Viewpoint - LyondellBasell has announced a reduction in its quarterly dividend to $0.69 per share, reflecting a $0.68 decrease from the previous quarter, as part of a strategy to better position the company during ongoing market challenges [1][2]. Group 1: Dividend Announcement - The board of directors declared a quarterly dividend of $0.69 per share, which is a reduction from the fourth quarter 2025 dividend [1] - The dividend payment is scheduled for March 9, 2026, with an ex-dividend and record date of March 2, 2026 [1]. Group 2: Financial Strategy and Market Position - In 2025, LyondellBasell returned approximately $2 billion to shareholders from existing cash and operations despite a prolonged industry downturn [2] - The company aims to prioritize safety and reliability in 2026 while implementing cost reductions and seeking new opportunities to enhance profitability [2] - LyondellBasell remains committed to returning 70% of free cash flow to shareholders throughout the business cycle [2]. Group 3: Company Overview - LyondellBasell is a leader in the global chemical industry, focusing on creating sustainable solutions and enabling a circular and low carbon economy [3] - The company is one of the largest producers of polymers and a leader in polyolefin technologies, developing high-quality products for various applications [3].

Company Overview - Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes through its Symphony System, which is a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression [3] Recent Developments - As of February 19, 2026, all prefunded warrants issued in the October 2025 private placement have been fully exercised, resulting in approximately 972,000 shares of common stock outstanding [1] - The company has cash exercisable warrants outstanding for approximately 1.5 million shares, with a cash exercise price of $7.00 or greater per share [1] Stock Information - Recent Schedule 13G filings by investors do not reflect the 1-for-4 reverse stock split that occurred on January 29, 2026, which may lead to discrepancies in reported beneficial ownership share amounts [2]